Surmodics | SRDX - Operating Profit


Surmodics reported $-5.64M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Abbott USD 2.25B 73M Dec/2025
Align Technology USD 224.71M 40.06M Dec/2025
Anika Therapeutics USD -4.28M 32.1M Mar/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Baxter International USD 201.2M 70.8M Sep/2025
Boston Scientific USD 1.24B 203M Dec/2025
EDAP TMS EUR -5.77M 228K Jun/2025
Edwards Lifesciences USD 370.3M 54.8M Dec/2025
Haemonetics USD 67.4M 8.9M Dec/2025
Heron Therapeutics USD -5.66M 782K Sep/2024
J&J USD 5.59B 1.81B Dec/2025
Merit Medical Systems USD 42.61M 4.41M Sep/2025
Mesa Laboratories USD 5.78M 2.27M Dec/2024
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Option Care Health USD 84.51M 1.8M Sep/2025
Stryker USD 1.97B 609M Dec/2025
Surmodics USD -5.64M 276K Sep/2024
Trinity Biotech USD -509K 6.27M Sep/2025